Scotland reports fewer COVID-19 hospitalizations with Omicron

By Nancy Lapid

(Reuters) – In Scotland, the Omicron variant of the coronavirus appears less likely to result in COVID-19 hospitalization than Delta, according to an analysis of early data that was posted ahead of peer review on Wednesday.

The updated statistics agree with data released earlier on Wednesday from South Africa and from England, also in advance of peer review.

At the University of Edinburgh, researchers tracked nearly 152,500 patients diagnosed with COVID-19, including 22,205 infected with the Omicron variant. Half of the Omicron-infected patients were under age 40.

The number of Omicron patients who needed to be hospitalized was 68% lower than what the researchers would have expected, based on the rate in patients infected with Delta.

The study only included patients diagnosed at primary care practices, however. It did not include patients who got tested for COVID-19 in National Health Service laboratories, who account for most of the patients admitted to hospitals, according to the report.

The Scottish researchers estimated that 7.6% of the Omicron cases were reinfections, compared with only 0.7% of infections caused by Delta. They also found that a third dose of vaccine provided “considerable additional protection against symptomatic disease.”

At Imperial College London, researchers who earlier this week reported no less severe disease with Omicron than with Delta have now said they saw evidence over the last two weeks of a 40% to 45% reduction in the risk of hospitalization for Omicron relative to Delta infections.

Researchers in both countries said they see evidence that vaccines remain effective at preventing severe illness with Omicron and that booster doses significantly improve the waning protection from the initial two doses.

Experts warn that efforts to determine the “severity” of Omicron are hampered by differing levels of immunity from vaccination and previous infection both among countries and within countries, now and when Delta was peaking.

They also warn that longer studies of Omicron infections in broader populations are needed.

(Reporting by Nancy Lapid and Christine Soares; Editing by Caroline Humer and Aurora Ellis)

By Nancy Lapid

(Reuters) – In Scotland, the Omicron variant of the coronavirus appears less likely to result in COVID-19 hospitalization than Delta, according to an analysis of early data that was posted ahead of peer review on Wednesday.

The updated statistics agree with data released earlier on Wednesday from South Africa and from England, also in advance of peer review.

At the University of Edinburgh, researchers tracked nearly 152,500 patients diagnosed with COVID-19, including 22,205 infected with the Omicron variant. Half of the Omicron-infected patients were under age 40.

The number of Omicron patients who needed to be hospitalized was 68% lower than what the researchers would have expected, based on the rate in patients infected with Delta.

The study only included patients diagnosed at primary care practices, however. It did not include patients who got tested for COVID-19 in National Health Service laboratories, who account for most of the patients admitted to hospitals, according to the report.

The Scottish researchers estimated that 7.6% of the Omicron cases were reinfections, compared with only 0.7% of infections caused by Delta. They also found that a third dose of vaccine provided “considerable additional protection against symptomatic disease.”

At Imperial College London, researchers who earlier this week reported no less severe disease with Omicron than with Delta have now said they saw evidence over the last two weeks of a 40% to 45% reduction in the risk of hospitalization for Omicron relative to Delta infections.

Researchers in both countries said they see evidence that vaccines remain effective at preventing severe illness with Omicron and that booster doses significantly improve the waning protection from the initial two doses.

Experts warn that efforts to determine the “severity” of Omicron are hampered by differing levels of immunity from vaccination and previous infection both among countries and within countries, now and when Delta was peaking.

They also warn that longer studies of Omicron infections in broader populations are needed.

(Reporting by Nancy Lapid and Christine Soares; Editing by Caroline Humer and Aurora Ellis)